Log In
BCIQ
Print this Print this
 

TAS-205

  Manage Alerts
Collapse Summary General Information
Company Taiho Pharmaceutical Co. Ltd.
DescriptionSelective prostaglandin D2 (PGD2) synthase inhibitor
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationMuscular dystrophy
Indication DetailsTreat Duchenne muscular dystrophy (DMD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today